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Abstract
Background: The Ras association domain family (RASSF) encodes for distinct tumor suppressors and several
members are frequently silenced in human cancer. In our study, we analyzed the role of RASSF2, RASSF3, RASSF4,
RASSF5A, RASSF5C and RASSF6 and the effectors MST1, MST2 and WW45 in thyroid carcinogenesis.
Results: Frequent methylation of the RASSF2 and RASSF5A CpG island promoters in thyroid tumors was observed.
RASSF2 was methylated in 88% of thyroid cancer cell lines and in 63% of primary thyroid carcinomas. RASSF2
methylation was significantly increased in primary thyroid carcinoma compared to normal thyroid, goiter and
follicular adenoma (0%, 17% and 0%, respectively; p < 0.05). Patients which were older than 60 years were
significantly hypermethylated for RASSF2 in their primary thyroid tumors compared to those younger than 40 years
(90% vs. 38%; p < 0.05). RASSF2 promoter hypermethylation correlated with its reduced expression and treatment
with a DNA methylation inhibitor reactivated RASSF2 transcription. Over-expression of RASSF2 reduced colony
formation of thyroid cancer cells. Functionally our data show that RASSF2 interacts with the proapoptotic kinases
MST1 and MST2 and induces apoptosis in thyroid cancer cell lines. Deletion of the MST interaction domain of
RASSF2 reduced apoptosis significantly (p < 0.05).
Conclusion: These results suggest that RASSF2 encodes a novel epigenetically inactivated candidate tumor
suppressor gene in thyroid carcinogenesis.
Background
Approximately 10% of the whole population develop a
clinically significant thyroid nodule during their lifetime
[1]. Nearly 80% of all thyroid malignancies arise from the
follicular epithelial cells, the thyrocytes. There are three
main histological types of epithelial thyroid cancer: the
papillary thyroid carcinoma (PTC), the follicular thyroid
carcinoma (FTC) and the undifferentiated (or anaplastic)
thyroid carcinoma (UTC). In contrast, medullary thyroid
carcinoma (MTC) develop from parafollicular C cells.
C cells produce calcitonin, a hormone regulating the
calcium metabolism [2].
Development and progression of thyroid tumors are a
consequence of complex epigenetic and genetic changes.
In our previous work, we have identified a novel
Ras effector, which is located at the tumor suppressor
gene locus 3p21.3 [3]. The gene termed Ras Association
Domain Family 1A (RASSF1A) is epigenetically inacti-
vated in human cancers and inhibits the growth of
tumors in vivo [4,5]. We and others have shown that
RASSF1A is frequently silenced in thyroid cancer [6-9].
RASSF1A hypermethylation was more pronounced in the
aggressive undifferentiated thyroid carcinoma [7,10].
Epigenetic inactivation of RASSF5 in thyroid cancer has
also been investigated [11,12].
RASSF1A was the first member of the Ras association
domain family (RASSF). The family consists of six classi-
cal RASSFs (RASSF1 to RASSF6) and the N-terminal
RASSFs (RASSF7 to RASSF10) with a N-terminal Ras
association (RA) domain [13-17]. The classical RASSFs
encode a C-terminal RA and SARAH domain [13,16].
Several of these genes (e.g. RASSF1A, RASSF2, RASSF5
[NORE1], RASSF6) encode tumor suppressors, which are
involved in cell cycle regulation, microtubule stability
and in apoptosis [13,16,18-20]. The SARAH domain is a
protein-protein interaction domain, named after the
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gue of human WW45), RASSF1 and Hippo (in D. mela-
nogaster; orthologue of the human proapoptotic kinase
MST1). SARAH domains are found in WW45, MST1
and all classical RASSFs. Heteromeric as well as homo-
meric interactions can be conducted via their SARAH
domains [21], e.g. MST and WW45 or RASSF1A and
RASSF5 interaction [22-24]. SARAH domains play a cen-
tral role in the newly discovered Hippo signaling pathway
in D. melanogaster, which regulates cell proliferation and
apoptosis [21,25].
The aim of our study was to reveal the epigenetic sta-
tus and function of RASSF2, RASSF3, RASSF4, RASSF5
and RASSF6 in thyroid carcinogenesis. Here, we report
that RASSF2 is frequently hypermethylated in thyroid
tumors and suppresses growth of thyroid cancer.
Results
Epigenetic inactivation of RASSF2 and RASSF5 in thyroid
cancer
In our study we aimed to reveal the role of the classical
RASSF members which harbor a C-terminal RA domain
and a SARAH domain and their effectors MST1, MST2
and WW45 in thyroid carcinogenesis. Since RASSF1A
function and silencing was already studied in detail, we
focused our work on RASSF2, RASSF3, RASSF4,
RASSF5A, RASSF5C and RASSF6 which all encode a C-
terminal SARAH domain [7,10,13]. First we analyzed
the promoter methylation of these genes in thyroid can-
cer cell lines (Fig. 1). RASSF6 contains the only promo-
t e r ,w h i c hi sn o tl o c a t e dw i t h i naC p Gi s l a n d[ 1 3 ]a n d
was not included in the methylation analysis. RASSF2
promoter hypermethyation was observed in seven out of
eight (88%) thyroid cancer cell lines (Fig. 1 and Tab. 1).
RASSF5A hypermethylation was found in all analyzed
cancer cell lines, however RASSF5C was only partially
methylated in 8305C and Hth74 (Fig. 1). RASSF5A and
RASSF5C are transcribed from different CpG island pro-
moters [13]. CpG island hypermethylation of RASSF2
and RASSF5A was confirmed by bisulfite sequencing
(additional file 1). CpG island promoter hypermethyla-
tion of RASSF3, RASSF4, MST1, MST2 and WW45 were
not found in thyroid cancer cell lines (Fig. 1). RASSF1A
methylation was analyzed previously and is summarized
in Table 1 [7,10]. RASSF1A was hypermethylated in all
analyzed thyroid cancer cell lines.
Next we analyzed the expression of RASSF2,
RASSF5A and RASSF5C in all thyroid cancer cell lines
and human fibroblasts (HF53) (Fig. 2). In human fibro-
blasts, which were unmethylated for all three promoters,
high expression of RASSF2 and RASSF5A was detected,
however RASSF5C expression was low (Fig. 2A). Expres-
sion of RASSF2 was reduced in several thyroid cancer
cell lines (e.g. FTC 236 and 1736). RASSF5A expression
was also diminished in different thyroid cancer cell lines
(Fig. 2A) compared to HF53. Additionally, two thyroid
cancer cell lines (FTC 236 and 1736) were treated with
5-Aza-2’-deoxycytidine (Aza) and RASSF2 and RASSF5A
expression was analyzed by qRT-PCR (Fig. 2B and 2C).
Inhibition of DNA methyltransferases by Aza induced
an upregulation of RASSF2 and RASSF5A expression. In
summary, we observed frequent epigenetic silencing of
RASSF2 and RASSF5A in thyroid cancer cell lines.
Frequent tumor-specific methylation of RASSF2 in
primary thyroid tumors
Subsequently, we analyzed the methylation of RASSF2
and RASSF5A promoter in 31 primary thyroid carcino-
mas (3 MTC, 10 FTC, 12 PTC and 6 UTC), 10 follicular
adenomas, 12 goiters and 12 normal thyroid controls
(Fig. 3 and Tab. 1). In 19 out of 30 (63%) thyroid carci-
nomas, the promoter of RASSF2 was partially methy-
lated (Tab. 1). In contrast, none of 12 normal thyroid
tissues and 10 follicular adenomas exhibited a methyla-
tion of RASSF2 (Fig. 3A). Only two out of 12 (17%) goi-
ters were methylated (Tab. 1). Statistical analysis
revealed a significant increase in RASSF2 methylation
frequency in thyroid cancer compared to normal thyroid
controls, follicular adenomas or goiters (p < 0.001, p =
0.001 or p = 0.015; Fisher’s exact test, respectively).
Furthermore, we examined the methylation frequency of
RASSF2 in different types of thyroid carcinoma (Tab. 1).
Medullary thyroid carcinoma showed the lowest fre-
quency (0/3 = 0%) in comparison to PTC (6/11 = 54%),
to FTC (8/10 = 80%) and to UTC (5/6 = 83%). Methyla-
tion of RASSF2 was significantly higher in thyroid
tumors obtained from older patients (90%; >60 year)
compared to those from younger patients (38%; <40
years; p = 0.043) or patients from 41 to 59 years (58%).
Other correlations with histopathological parameters
were not revealed. We also analyzed the RASSF5A
methylation in primary thyroid cancers and other thyr-
oid tissues (Fig. 3B). RASSF5A methylation was fre-
quently found in cancer cell lines (9/9 = 100%) and
primary thyroid cancer but was also detected in all ana-
lyzed control tissues, goiters and follicular adenomas
(Tab. 1). Since RASSF5A methylation was not tumor
specific, we further focused on RASSF2 where methyla-
tion was preferentially found in cancers.
Functional analysis of RASSF2
Next, we analyzed the distinct tumor suppressive fea-
tures associated with RASSF2. First, the localization of
RASSF2 and the other classical RASSFs was investigated
in FTC133 cells (Fig. 4). RASSF1A and RASSF1C are
both found in the cytoplasm together with microtubule.
The other RASSFs (RASSF2, Rassf3, RASSF4, RASSF5
a n dR A S S F 6 )w e r en o ta s s o c i ated with microtubule but
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Page 2 of 12Figure 1 Methylation of RASSFs, MSTs and WW45 in thyroid cancer cell lines. The methylation status of the indicated CpG islands was
analyzed by COBRA. PCR products (for length see Additional file 5, Table S1) from bisulfite-treated DNA were digested (+) and mock digested
(-) with TaqI or HpyCH4IV and resolved on 2% gel. In vitro methylated DNA (methy.) was utilized as positive control. The sizes of a 100 bp ladder
(M) are indicated. Methylated (m), partially methylated (p) and unmethylated (u) samples were determined.
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Page 3 of 12were observed in the cytoplasm and nucleus (Fig. 4 and
data not shown). For Rassf3, RASSF4, RASSF5 and
RASSF6 cluster formation was detected (Fig. 4 and data
not shown). Deletion of the SARAH domain did not
alter the localization of the fluorescent RASSF2, Rassf3
and RASSF6. However RASSF1A and RASSF4 appear to
localize to nucleus from cytoplasm. It is interesting to
note that the utilized RASSF5A isoform (variant 4) con-
tains a partially truncated SARAH domain. The SARAH
domain is a protein-protein interaction domain, which
is found in all classical RASSFs and their proapoptotic
effector MST1 and MST2 and the adapter protein
WW45. Therefore, we analyzed the interaction of these
proteins in yeast two hybrid and pull down assays
(Table 2 and Fig. 5). We found an interaction of all
Table 1 Summary of RASSF2, RASSF5A and RASSF1A
methylation analyses
RASSF2 RASSF5A RASSF1A
c
thyroid cancer cell lines 7/8 (88%) 9/9 (100%) 9/9 (100%)
primary thyroid cancer 19/30 (63%)
a, b 26/31 (84%) 26/31 (84%)
MTC 0/3 (0%) 1/3 (33%) 5/6 (83%)
PTC 6/11 (54%) 9/12 (75%) 8/13 (62%)
FTC 8/10 (80%) 10/10 (100%) 7/10 (70%)
UTC 5/6 (83%) 6/6 (100%) 7/9 (77%)
follicular adenoma 0/10 (0%)
a 10/10 (100%) 7/10 (70%)
goiter 2/12 (17%)
b 12/12 (100%) 9/12 (75%)
control tissue 0/12 (0%)
a 12/12 (100%) -
significant differences:
aprimary thyroid carcinoma vs. follicular adenoma or
primary thyroid carcinoma vs. normal thyroid (p≤0.001, Fisher’s exact test);
b
primary thyroid carcinoma vs. goiter (p = 0.015, Fisher’s exact test);
c [7,10].
Figure 2 RASSF2 and RASSF5 expression in thyroid cancer cell lines. cDNA isolated from thyroid cancer cell lines and human fibroblasts
(HF53) were amplified by RT-PCR (for primer and conditions see Additional file 6, Table S2) together with a water control (H2O). PCR products
were resolved on 2% gel together with a 100 bp ladder (M). Expression of b-actin (230 bp) was determined as a control for RNA integrity. B.
Reexpression of RASSF2 was analyzed by qRTPCR in thyroid cancer cell lines FTC133 and 1736 treated for 4 days with indicated concentrations of
5-aza-2’-deoxycytidine (Aza). RNA levels were normalized to b-actin and calculated relative to human fibroblasts (= 100) C. Reexpression of
RASSF5A after Aza treatment.
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assay (additional file 2). However, truncation of the
SARAH of RASSF5A (variant 4) and RASSF2 reduced
the interaction in the yeast two hybrid or abolished
interaction in the pulldown assay (Fig. 5, additional file
2 and additional file 3). Interaction of WW45 with
RASSF1A, RASSF3, RASSF4 and MST1 and MST2 in
the yeast two hybrid was found. Precipitation of MST1
with WW45, RASSF1A, RASSF2, RASSF3, RASSF5C
and RASSF6 was also confirmed by pull down (Tab. 2
and Fig. 5). Interaction of RASSF2 with RASSF1A,
RASSF3 and RASSF5C was only found in yeast two
hybrid assay (Tab. 2).
RASSF2-induced growth suppression and apoptosis in
thyroid cancer
The interaction of RASSF2 with kinases MST1 and
MST2 indicate that RASSF2 is involved in the proapop-
totic RASSF-pathway. Therefore, we analyzed RASSF2-
induced growth suppression and apoptosis in thyroid
cancer cell lines (Fig. 6). The thyroid cancer cell line
1736 was transfected with a construct expressing
RASSF2 under control of the CMV promoter or an
empty vector (Fig. 4). After selection for 4 weeks a 65%
decrease of colony formation in cancer cells transfected
with RASSF2 (mean = 4.6) compared to cells transfected
with the empty vector (mean = 13.6; p = 0.019, one-way
ANOVA test) was observed (Fig. 6A and 6B). Addition-
ally, we analyzed the RASSF2 induced apoptosis in 1736
and FTC133 cells (Fig. 6C and 6D; additional file 4).
Transfection of fluorescent RASSF2 caused a signifi-
cantly increased apoptosis indicated by nuclei condensa-
tion/fragmentation compared to the fluorescent vector
in 1736 and FTC133 (p < 0.001 and p = 0.07, respec-
tively). Apoptotic cells were exemplarily verified by
TUNEL assay (Fig. S4). In FTC1736 the ratio of intact
vs. apoptotic cells was for the vector: 96% vs. 4%; for
RASSF2wt: 88% vs. 12% and for RASSF2ΔSARAH: 94%
vs. 6%, respectively. In FTC133 a similar trend was
o b s e r v e d( F i g .6 D ) .F o rF T C 1 3 3t h er a t i oo fi n t a c tv s .
apoptotic cells was the following for the vector: 75% vs.
25%; for RASSF2wt: 62% vs. 38% and for RASSF2Δ-
SARAH: 78% vs. 22%, respectively. Thus, RASSF2Δ-
SARAH exhibited a significantly reduced rate of
apoptotic cells in 1736 and FTC133 cells compared to
wt RASSF2 (p < 0.05). In summary, our data suggest
that RASSF2 tumor suppression function involves apop-
totic regulation through binding of the proapoptotic
kinases MST.
Discussion
Epigenetic inactivation of tumor suppressor genes is a
fundamental event in the pathogenesis of malignant
tumors. Here we report that RASSF2, a member of the
Figure 3 Methylation of RASSF2 and RASSF5A in primary tissue. A. COBRA of RASSF2 in primary thyroid specimen, including follicular
thyroid cancer (FTC), papillary thyroid cancer (PTC), medullary thyroid cancer (MTC), undifferentiated thyroid cancer (UTC), goiter (G) normal
thyroid samples (N) and follicular adenoma (FA). PCR products from bisulfite-treated DNA were digested (+) and mock digested (-) with TaqI and
resolved on 2% gel. B. Methylation status of RASSF5A. In vitro methylated DNA (methy.) was utilized as positive control. The sizes of a 100 bp
ladder (M) are indicated. Methylated (m), partially methylated (p) and unmethylated (u) samples were determined.
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Page 5 of 12Ras Association Domain family, is frequently silenced in
primary thyroid tumor and thyroid cancer cell lines. To
t h eb e s to fo u rk n o w l e d g et h i si st h ef i r s tr e p o r tt h a t
shows that the epigenetic inactivation of RASSF2 is a
common event in thyroid carcinogenesis. We also show
that RASSF2 suppressed growth of thyroid cancer cells.
The RASSF2 transcript can be detected in most normal
tissues [20]. Down-regulation of RASSF2A by promoter
hypermethylation has been shown in different tumor
cell lines and primary tumors, including lung cancer,
colon cancer, gastric cancer, nasopharyngeal carcinoma,
head and neck cancer [20,26-33]. It has been reported
that primary colorectal cancers, which showed KRAS or
BRAF mutations, also frequently showed RASSF2 methy-
lation, and inactivation of RASSF2 enhanced KRAS-
induced oncogenic transformation [28,30]. RASSF2
binds directly to K-Ras in a GTP-dependent manner via
the Ras effector domain [20]. In addition, patients with
methylated RASSF2A promoter presented a higher fre-
quency of lymph node metastasis [27]. Methylation of
RASSF1A and RASSF2 was associated with poor out-
come after radiotherapy in oral squamous cell carci-
n o m a[ 3 4 ] .H e r ew er e p o r tt h a tt h ed e g r e eo fRASSF2
methylation was associated with the age of thyroid can-
cer patients. It has been suggested that aberrant methy-
lation of RASSF2 in plasma of colorectal cancer patients
may serve as a cancer biomarker [35]. Thus, it will be
interesting to determine hypermethylation of RASSF2 in
blood samples of thyroid cancer patients.
Regarding RASSF2’s interaction with other RASSF
members, it was shown to associate with RASSF3 and
RASSF5 [29]. Our yeast two hybrid assay confirmed
these bindings and additionally binding of RASSF1A
and RASSF2 was observed. However these interactions
were not observed in pulldown (Tab. 2). In general only
the strong yeast two hybrid interactions could be
Figure 4 Localization of fluorescent RASSFs and RASSFΔSARAHs (deletion of SARAH domain).F T C 1 3 3c e l l sw e r et r a n s f e c t e dw i t ht h e
indicated fluorescent RASSFs and control vector (pEGFP). After one day cells were fixed and stained with DAPI.
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are prone to false positive results, we rather agree with
the pull down interactions. RASSF2 also binds both
proapoptotic kinases MST1 and MST2 in yeast two
hybrid assays and this was confirmed for RASSF2 and
MST1 by pulldown. It has been suggested that binding
of the classical RASSFs, MST1, MST2 and WW45 with
each other is conducted by their SARAH domains [21].
Deletion of the SARAH domain of RASSF2 abolished
binding with MST1 and MST2 [36,37]. It is interesting
to note that all RASSFs and WW45 bind MST1, how-
ever only certain RASSFs (e.g. RASSF1A and RASSF5C)
bind each other in pulldowns. This result suggests that
SARAH domains show different binding properties.
RASSF2 exhibits several tumor suppressor properties,
like inhibition of cell growth and induction of apoptosis
[20,27]. Here we show that RASSF2 also acts as a novel
tumor suppressor in thyroid carcinogenesis. It has been
shown that RASSF2 binds and regulates the proapopto-
tic kinases MST1 and MST2 [36,37]. RASSF2 also
engages the JNK pathway and induces apoptosis in an
MST1-independent manner [37]. Other findings suggest
that MST2 and RASSF2 form a complex, in which
RASSF2 is maintained in a phosphorylated state by
MST2 and protects MST2 from degradation and turn-
over [36]. However, the exact phosphorylation site of
RASSF2 by MST2 was not revealed.
Additionally, we have found that RASSF5A is frequently
hypermethylated in thyroid tissues, however methylation
was not tumor specific since it was also observed in con-
trols. Epigenetic silencing of RASSF5 in thyroid cancer
has been analyzed previously, but was also not tumor
specific [11,12]. Interestingly, RASSF5A and RASSF2
methylation was reduced in MTC compared to other
cancers. It has been reported that RASSF5A expression is
suppressed in FTC carrying PAX8-PPARg fusions [11].
Methylation of the other investigated CpG island promo-
ters of RAS effectors (RASSF3, RASSF4, MST1, MST2
and WW45) was uncommon.
Conclusions
In summary, we report frequent tumor-specific hyper-
methylation of RASSF2 in thyroid cancer. Functional
Table 2 Summary of interaction analyses
interaction partners interaction in
Y2H
interaction in
pulldown
MST1/
MST2
RASSF1A +/+ +/na
RASSF2 +/+ +/na
RASSF3 +/+ +/na
RASSF4 +/+ +/na
RASSF5A
(V4)
w/w -/na
RASSF5C +/+ +/na
RASSF6 +/+ +/na
WW45 +/+ +/na
WW45 RASSF1A w -
RASSF2 - -
RASSF3 w -
RASSF4 w -
RASSF5A
(V4)
wn a
RASSF6 - -
RASSF1A RASSF1A + -
RASSF2 - -
RASSF3 - -
RASSF4 - -
RASSF5A
(V4)
--
RASSF6 - -
RASSF2 RASSF1A w -
RASSF2 - -
RASSF3 + -
RASSF4 - -
RASSF5A
(V4)
--
RASSF6 - -
RASSF3 RASSF1A - -
RASSF2 - -
RASSF3 w w
RASSF4 + -
RASSF5A
(V4)
-n a
RASSF6 - -
RASSF4 RASSF1A - -
RASSF2 - -
RASSF3 + -
RASSF4 - -
RASSF5A
(V4)
--
RASSF6 - -
RASSF5C RASSF1A + w
RASSF2 + -
RASSF3 - na
RASSF4 w -
RASSF5A
(V4)
-n a
RASSF6 -
Table 2: Summary of interaction analyses (Continued)
RASSF6 RASSF1A - -
RASSF2 - -
RASSF3 - -
RASSF4 - -
RASSF5A
(V4)
--
RASSF6 - na
+, positive interaction; -, no interaction; w, weak interaction; na, not analyzed.
Schagdarsurengin et al. Molecular Cancer 2010, 9:264
http://www.molecular-cancer.com/content/9/1/264
Page 7 of 12Figure 5 Binding studies of RASSFs, MST1 and WW45 in co-precipitation. Plasmids, that express the indicated GST-Flag-tagged-constructs
(-GF) and Flag-tagged-constructs (-F) were transfected into HEK293T cells. After two days, total protein was extracted and Flag-tagged proteins
were precipitated with anti-Flag-agarose (F) or glutathione sepharose (G). Samples were separated on a 10% PAGE gel and blotted. The
precipitated and co-precipitated proteins were determined with anti-Flag-antibodies. The sizes of a protein marker (M) are indicated.
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poptotic kinases MST1 and MST2. Overexpression of
RASSF2 induces apoptosis in thyroid cancer cell lines.
These data suggest that RASSF2 acts as a proapoptotic
tumor suppressor in thyroid carcinogenesis.
Methods
Tissues and cell lines
65 thyroid tissues, including 31 primary thyroid carcino-
mas (6 UTC, 3 MTC, 10 FTC, and 12 PTC), 10 follicu-
lar adenomas, 12 goiters and 12 normal thyroid samples
were analyzed [7,10]. All patients signed informed con-
sent at initial clinical investigation. The study was
approved by local ethic committees. The mean age of
the study population at the time of surgical resection
was 51 ± 15 years and 40% of the patients were male.
Nine human thyroid cancer cell lines: BcPaP (PTC),
FTC238, FTC236, FTC133, C643 (UTC), 8505C (UTC),
1736 (UTC), 8305C (UTC) and HTh74 (UTC) were cul-
tured in the recommended medium and included in this
study [7,10]. Genomic DNA was extracted from frozen
tissues and cultured cells by a standard phenol/chloro-
form procedure.
Methylation analysis
Methylation of promoter regions (RASSF2, RASSF3,
RASSF4, RASSF5A, RASSF5C, WW45, MST1 and MST2)
was determined by COBRA and bisulfite sequencing
[38,39]. Briefly, 100 ng of bisulfite-treated DNA were
amplified with 10 pmol of primers in a reaction buffer
containing 0.2 mM dNTP mix, 1.5 mM MgCl2, 10 pmol
of each primer and 1.5 U Taq polymerase (InViTek
GmBH, Berlin, Germany). For PCR primers and condi-
tion see additional file 5. 20 to 50 ng of PCR products
Figure 6 Tumor suppressor function of RASSF2. A. The RASSF2 was cloned in pCMV-Tag1 and transfected in thyroid cancer cell line 1736 in
parallel with empty vector in triplicates. Cells were grown in selective medium for four weeks and stained with Giemsa. B. Numbers of colonies
were determined and means with standard deviation were plotted. C. 1736 cells were transfected with the indicated fluorescent RASSF2
constructs and control vector (pEYFP). After two days cells were fixed and stained with DAPI. Fluorescent cells (n > 200) were counted and the
percentage of intact, condensed, fragmented and missing nuclei were determined. D. Nuclei alterations in FTC133 cells (n > 100).
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Frankfurt, Germany) and analyzed on a 2% Tris-borate
EDTA agarose gel. For bisulfite sequencing PCR pro-
ducts were cloned in the pGEM-T vector (Promega,
Heidelberg, Germany) and sequenced (Genterprise,
Mainz, Germany).
Expression analysis
Two thyroid cancer cell lines (1736 and FTC236) were
treated for 4 days with 5 μMo r1 0μM of 5-aza-dC
(Sigma, Taufkirchen, Germany). RNA was isolated using
TRIzol-Reagent (Invitrogen, Karlsruhe, Germany). To
eliminate DNA contamination 1 μg RNA was incubated
with 1U DNase I (Fermentas GmbH, St. Leon-Rot, Ger-
many), 1 μl 10X DNase I buffer and DEPC-treated
water in 10 μl. After 15 minutes incubation at room
temperature DNase was inactivated by adding 1 μlo f2 5
m ME D T Aa n di n c u b a t i o na t6 5 ° Cf o r1 5m i na n d
reversely transcribed using poly-dT primers and random
hexamers in 20 μl of RT-mix with MMLV reverse tran-
scriptase (Promega, Heidelberg, Germany) for 1 h at 42°
C. Subsequently, 2 μl of cDNA was amplified. For PCR
primers and condition see additional file 6.
Statistical evaluation
Statistical analysis was carried out using SPSS17 (SPSS,
München, Germany). Categorical variables were plotted
into contingency tables and evaluated using Fisher’s
exact test or one way ANOVA test. All reported
p-values are two-sided and considered significant for
p < 0.05.
Constructs
The cDNAs of RASSF2, RASSF3, RASSF4, RASSF5A
(variant 4), RASSF5C (variant 3), RASSF6, MST1,
MST2 and WW45 were cloned after amplification
of fragments from EST-clones DKFZp781O1747Q,
IMAGp998A0813502Q, IRAKp961I1269Q, IRALp
962N0113Q (BC004270), IRAKp961L2026Q; DKFZp
686K23225Q, IRAKp961C0282Q, IRAKp961I0613Q and
IRAKp961L0427Q (RZPD, Berlin, Germany), respec-
tively. RASSF1A, RASSF1C and Rassf3 were described
previously [3,40]. Mutant forms of constructs were gen-
erated with the QuickChange® XL Site-Directed Muta-
genesis Kit (Stratagene, La Jolla, USA) and appropriate
primers. All constructs were confirmed by sequencing.
Localization studies
cDNAs were cloned into the fluorescence vector pEYFP
(Clontech, Mountain View, USA). After transient trans-
fection into FTC133 cells with HEKfectin (BioRad,
München, Germany), the localization of fluorescent
RASSF variants and the vector control were investigated
with a fluorescence microscope (Axio Observer Z1
Zeiss, Jena, Germany). Nuclei of the cells were visualized
by staining with DAPI (0,1 μg/ml in PBS).
Interaction studies using the yeast two-hybrid system
The Matchmaker Two-hybrid system (Clontech, Moun-
tain View, USA) was utilized. The yeast strain PJ69-4A
was co-transformed with 0.5 μg of each plasmid using
the PEG/LiAc method. The interaction analysis was car-
ried out on SD minimal medium plates without adenine
and histidine and the transformation efficiency was
determined on SD plates with adenine and histidine.
The strength of interaction was investigated by quantifi-
cation of the expression of the b-galactosidase reporter
gene with o-nitrophenyl-b-D-galactopyranoside (ONPG)
as substrate at OD 420 nm.
Interaction studies by co-precipitation
cDNAs were cloned into the vector pCMV-Tag1 (Stra-
tagene, La Jolla, USA) and/or in the modified vector
pEBG (GST and FLAG tag). To investigate the interac-
tion of specific RASSF forms, MST1, MST2 and
WW45, co-transfections with HEKfectin (BioRad,
München, Germany), were performed in HEK293T
cells. Two days after transfection, total protein was
extracted in FLAG-lysis buffer. The GST-fused proteins
were precipitated with glutathione-sepharose (Amer-
sham Biosciences, Freiburg, Germany). FLAG-tagged
proteins were precipitated with anti-Flag-agarose
(Sigma, Steinheim, Germany). Samples were separated
on a 10% PAGE gel and blotted. The interaction was
determined with anti-FLAG-antibodies (Sigma, Stein-
heim, Germany).
Proliferation assays
RASSF2 was cloned into the vector pCMV-Tag1 (Strata-
gene, La Jolla, USA). The thyroid cancer cell line 1736
was transfected using HEKfectin (BioRad, München,
Germany). Colonies were selected under 1 mg/ml
Geneticin (Gibco, Karlsruhe, Germany) in DMEM for 4
weeks. Expression of RASSF2 was confirmed by RT-
PCR (data not shown).
Apoptotic assays
Thyroid cancer cells FTC133 and 1736 were seeded on
glass slides and transfected with different RASSF2 con-
structs using HEKfectin (BioRad, München, Germany)
and analyzed after two days of incubation. Therefore
cells were fixed with paraformaldehyde, permeabilized
with TritonX, DAPI stained and embedded in MOWIOL
for fluorescent analysis. Transfected cells (n > 100 for
FTC133 and n > 200 for 1736) were analyzed for intact,
condensed, fragmented or missing nucleus.
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